Advertisement

Acute Reaction to Pentavalent Vaccine

  • Darko RichterEmail author
Chapter

Practical Points

  • Anaphylaxis to vaccines is rare; approximately once in one million doses

  • Anaphylaxis usually occurs within the first 30 min after exposure, but sometimes it can take up to 4 h or longer

  • Symptoms of anaphylaxis are polymorphic, but well systematized and should be readily recognized and carefully appreciated

  • Anaphylaxis should be acutely treated with adrenaline, systemic corticosteroids, volume replacement, and antihistamines

  • Twenty-four-hour hospital observation is indicated because a biphasic course is possible in anaphylaxis

  • Diagnosis relies on skin testing with the culprit vaccine and its components, and where available, in vitro tests for the specific IgE to vaccine additives

  • Anaphylaxis contraindicates further immunization with the culprit vaccine; in exceptional vital situations, a desensitization-immunization graded dose protocol may be attempted in an intensive care setting

Keywords

Diphtheria-tetanus-3-component acellular pertussis Inactivated polio Haemophilus influenzae type b Pentavalent vaccine 

References

  1. 1.
    Muraro A, Roberts G, Worm M, Bilo MB, Brockow K, Fernandez Rivas M, Santos AF, Zolkipli ZQ, Bellou A, Beyer K, Bindslev-Jensen C, Cardona V, Clark AT, Demoly P, Dubois AE, DunnGalvin A, Eigenmann P, Halken S, Harada L, Lack G, Jutel M, Niggemann B, Rueff F, Timmermans F, Vlieg-Boerstra BJ, Werfel T, Dhami S, Panesar S, Akdis CA, Sheikh A. Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology. Allergy. 2014;69(8):1026–45.CrossRefGoogle Scholar
  2. 2.
    Muraro A, Roberts G, Clark A, et al. EAACI task force on anaphylaxis in children. The management of anaphylaxis in childhood: position paper of the European academy of allergology and clinical immunology. Allergy. 2007;62:857–71.CrossRefGoogle Scholar
  3. 3.
    McNeil MM, Weintraub ES, Duffy J, Sukumaran L, Jacobsen SJ, Klein NP, et al. Risk of anaphylaxis after vaccination in children and adults. J Allergy Clin Immunol. 2015;137(3):868–78.CrossRefGoogle Scholar
  4. 4.
    Wood RA. Allergic reactions to vaccines. Pediatr Allergy Immunol. 2013;24(6):521–6.CrossRefGoogle Scholar
  5. 5.
    Sampson HA. Anaphylaxis and emergency treatment. Pediatrics. 2003;111(6 Pt 3):1601–8.PubMedGoogle Scholar
  6. 6.
    Lieberman P. Biphasic anaphylactic reactions. Ann Allergy Asthma Immunol. 2005;95(3):217–26; quiz 26, 58.CrossRefGoogle Scholar
  7. 7.
    Edelman K, Malmstrom K, He Q, Savolainen J, Terho EO, Mertsola J. Local reactions and IgE antibodies to pertussis toxin after acellular diphtheria-tetanus-pertussis immunization. Eur J Pediatr. 1999;158(12):989–94.CrossRefGoogle Scholar
  8. 8.
    Dannemann A, van Ree R, Kulig M, Bergmann RL, Bauer P, Forster J, Guggenmoos-Holzmann I, Aalberse RC, Wahn U. Specific IgE and IgG4 immune responses to tetanus and diphtheria toxoid in atopic and nonatopic children during the first two years of life. Int Arch Allergy Immunol. 1996;111(3):262–7.CrossRefGoogle Scholar
  9. 9.
    Brockow K, Romano A, Blanca M, Ring J, Pichler W, Demoly P. General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy. 2002;57(1):45–51.PubMedGoogle Scholar
  10. 10.
    Nilsson L, Brockow K, Alm J, Cardona V, Caubet JC, Gomes E, Jenmalm MC, Lau S, Netterlid E, Schwarze J, Sheikh A, Storsaeter J, Skevaki C, Terreehorst I, Zanoni G. Vaccination and allergy: EAACI position paper, practical aspects. Pediatr Allergy Immunol. 2017;28(7):628–40.CrossRefGoogle Scholar
  11. 11.
    Martin-Munoz MF, Pereira MJ, Posadas S, Sanchez-Sabate E, Blanca M, Alvarez J. Anaphylactic reaction to diphtheria-tetanus vaccine in a child: specific IgE/IgG determinations and cross-reactivity studies. Vaccine. 2002;20(27–28):3409–12.CrossRefGoogle Scholar
  12. 12.
    Mayorga C, Torres MJ, Corzo JL, Alvarez J, Garcia JA, Rodriguez CA, Blanca M, Jurado A. Immediate allergy to tetanus toxoid vaccine: determination of immunoglobulin E and immunoglobulin G antibodies to allergenic proteins. Ann Allergy Asthma Immunol. 2003;90(2):238–43.CrossRefGoogle Scholar
  13. 13.
    Arroabarren E, Anda M, Sanz ML. Anaphylaxis to pneumococcal vaccine; CRM(197): novel cause of vaccine allergy. Pediatr Allergy Immunol. 2016;27(4):433–7.CrossRefGoogle Scholar
  14. 14.
    Caubet JC, Rudzeviciene O, Gomes E, Terreehorst I, Brockow K, Eigenmann PA. Managing a child with possible allergy to vaccine. Pediatr Allergy Immunol. 2014;25(4):394–403.CrossRefGoogle Scholar
  15. 15.
    Richter D. Allergies to vaccines in children. Central Eur J Paediatr. 2017;13(1):24–9.CrossRefGoogle Scholar
  16. 16.
    Chapman LE, Sullivent EE, Grohskopf LA, Beltrami EM, Perz JF, Kretsinger K, Panlilio AL, Thompson ND, Ehrenberg RL, Gensheimer KF, Duchin JS, Kilmarx PH, Hunt RC, Centers for Disease Control and Prevention (CDC). Recommendations for postexposure interventions to prevent infection with hepatitis B virus, hepatitis C virus, or human immunodeficiency virus, and tetanus in persons wounded during bombings and other mass-casualty events-United States, 2008: recommendations of the Centers for Disease Control and Prevention (CDC). MMWR Recommend Rep. 2008;57(Rr-6):1–21; quiz CE1–4.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Outpatient and Emergency Service, Department of PediatricsUniversity Hospital CenterZagrebCroatia

Personalised recommendations